Jaypirca (pirtobrutinib) — CareFirst (Caremark)
Marginal zone lymphoma (MZL)
Initial criteria
- Subsequent treatment of relapsed, refractory, or progressive MZL which may include extranodal (gastric or non-gastric MALT lymphoma), nodal marginal zone lymphoma, or splenic marginal zone lymphoma
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months